Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET: JCAR015 in Adult B-ALL
NCT02535364Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Aug 2015
- Primary completion
- Apr 2017
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Vadacabtagene leraleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Celgene Corporation. Primary endpoint: Percentage of Participants With Complete Remission (CR) or Complete Remission With Incomplete Hematopoietic Recovery (CRi) at 12 months. Started Aug 2015; status: terminated.
02
Drugs
Vadacabtagene leraleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02535364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535364.